Trial Profile
A Randomised, Parallel-group, Open-label Phase II Trial of the Immunological Effects of Three Regimens of GX301 Vaccination in Castration-resistant Prostate Cancer Patients Who Have Achieved Response or Disease Stability With First-line Chemotherapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Dec 2021
Price :
$35
*
At a glance
- Drugs GX 301 (Primary) ; Imiquimod; Montanide ISA-51
- Indications Prostate cancer
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Laboratoires Leurquin-Mediolanum
- 01 Dec 2021 Results published in the Cancer Immunology Immunotherapy
- 21 Jul 2020 Status changed from active, no longer recruiting to completed.
- 19 Jan 2020 This trial is completed in Spain, according to European Clinical Trials Database record.